Studies rimegepant as a migraine preventive treatment in patients
Studies how well rimegepant prevents migraine and how well it is tolerated, in adults.
Plain-language title generated from the registry record
Registry title: RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
Key facts
- Where
- Florence and Pavia, ItalySee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine, with or without aura, who have at least 4 migraine days a month. It studies rimegepant as a treatment to prevent migraine.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Migraine without aura or migraine with aura (ICHD-III), with at least 4 migraine days a month.
- Earlier treatment
- People cannot have changed their preventive migraine treatment in the month before the first dose of rimegepant.
Main reasons for not taking part
- Contraindications for use of gepants
- Diagnosis of chronic migraine
- Other medical diseases that might interfere with study assessments
- Pregnancy and breastfeeding
- Change in preventive treatment in the month before the first dose
Read by machine on 9 November 2026.
Where in Italy
- SOD Centro Cefalee e Farmacologia Clinica, AOU CareggiFlorence, ItalyTaking people
- IRCCS National Neurological Institute "C. Mondino" FoundationPavia, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Florence
- Trial code
- NCT06409832
- Record updated
- 11 June 2026
- Original description
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.Read full original descriptionShow less
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Inclusion: Diagnosis of migraine without aura or migraine with aura, according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III); At least 4 monthly migraine days; Good compliance to study procedures; Availability of headache diary at least of the preceding months before enrollment.
Exclusion: Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments; Changes in preventive treatments in the month before the first administration of rimegepant; Subjects with contraindications for use of gepants; Diagnosis of chronic migraine; medical comorbidities that could interfere with study results; Pregnancy and breastfeeding.